TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
20 hedge funds and large institutions have $46.3M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 8 closing their positions.
5% less funds holding
Funds holding: 21 → 20 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
18% less capital invested
Capital invested by funds: $56.3M → $46.3M (-$10M)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$239K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$216K |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$183K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$44.6K |
| 5 |
BJ
BlackRock Japan
Tokyo,
Japan
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$372K |
| 2 |
VAM
Visium Asset Management
New York
|
-$293K |
| 3 |
SIM
Spark Investment Management
New York
|
-$186K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$173K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$171K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$31K | -11 | Closed |
|
27
Citigroup
New York
| – | -$12K | -4 | Closed |
|
|
PCM
28
Prelude Capital Management
New York
| – | -$1K | -1 | Closed |
|
TCON Hedge Fund Activity: Q2 2015 in Review
20 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2015, worth a combined $46.3M — down 18% from $56.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TCON and 7 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, opening a new position worth an estimated $239K. The largest seller was Millennium Management, exiting entirely with an estimated $372K sold.
- 20 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2015, down from 21 in Q1 2015.
- Funds reported $46.3M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2015, down 18% quarter-over-quarter.
- 7 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2015 and 8 closed out, a net change of -1 holder.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2015 was Vanguard Group, an estimated $239K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2015 was Millennium Management, an estimated $372K sold.
Based on aggregated 13F filings for Q2 2015.